Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma

Purpose

To learn about the possible effects of a prebiotic food-enriched diet (PreFED) targeting the gut microbiome in participants with melanoma who are starting immune checkpoint blockade (ICB) therapy.

Condition

  • Unresectable Melanoma

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥18 years old - English-speaking - Body mass index (BMI) 18.5-45 kg/m2 - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Histologically confirmed stage III/IV, unresectable cutaneous, uveal, acral or mucosal melanoma. Asymptomatic brain metastases are allowed. - Planned initiation of 1st line standard-of-care approved immune checkpoint blockade (anti-PD1 +/- anti-CTLA4 or anti-LAG3 inhibitors) in the metastatic setting (prior ICB in the adjuvant setting is allowed. - Returning to MD Anderson for restaging and follow-up (ICB treatment may occur locally) - Measurable disease per RECIST 1.1 or RANO criteria. Up to 10 patients without measurable can be enrolled. - WOCP must have negative UPT within 1 week of beginning dietary intervention. - Self-reported willingness to eat the provided foods (with some tailoring to their food preferences) - Self-reported willingness to comply with scheduled visits, undergo venipuncture, provide stool samples.

Exclusion Criteria

  • Previous ICB treatment in the metastatic setting - History of inflammatory bowel disease, total colectomy, or bariatric surgery. - Currently taking steroids > Prednisone 10 mg/day or equivalent - Medical contraindications to the Intervention Diet as determined by the treating physician. - Self-reported major dietary restrictions, including but not limited to relevant food allergies, celiac disease, or diets such as vegan, ketogenic, extended fasting. - Insulin-dependent diabetes or condition requiring bile acid sequestrants - Unable or unwilling to undergo study procedures. - IV antibiotic use in the past month or oral antibiotic use in past 2 weeks. - Regularly taking supplements containing prebiotics, fiber and/or probiotics, and unable/unwilling to discontinue for the purpose of the study. - Current smoker or heavy drinker (defined as >14 drinks per week) or current illicit drug use. - Currently pregnant, planning to become pregnant, or lactating. - Concurrent malignancy requiring systemic therapy other than hormonal therapy. - Cognitively impaired adults

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Supportive Care
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Prebiotic food-enriched diet (PreFED)
Participants will receive prebiotic food-enriched snacks and supportive nutritional counseling to increase prebiotic foods in the diet.
  • Other: Prebiotic Food-Enriched Diet
    Given by PO

Recruiting Locations

MD Anderson Cancer Center
Houston 4699066, Texas 4736286 77030
Contact:
Erez Baruch, MD,PHD
713-745-5530
ENBaruch@mdanderson.org,

More Details

Status
Recruiting
Sponsor
M.D. Anderson Cancer Center

Study Contact

Erez Baruch, MD,PHD
713-745-5530
ENBaruch@mdanderson.org,

Detailed Description

Primary Objectives • Evaluate the effect of dietary intervention on the abundance of Faecalibacterium in stool samples from baseline to 12 weeks Secondary Objectives - Determine the best overall response rate (BORR) to PreFED + ICB regimens and landmark ORR at 12 weeks (intervention) and 24 weeks (maintenance) - Determine progression-free survival (PFS) and overall survival (OS) with PreFED + ICB regimens - Compliance and adherence to the dietary intervention at 12 weeks and maintenance at 24 weeks - Determine the safety (diet-related AEs) and tolerability (GSRS-IBS) of the dietary intervention at 12 weeks and maintenance at 24 weeks - Assess the rate of immune related adverse events in patients on ICB regimens receiving dietary intervention at 12 weeks and maintenance at 24 weeks - Assess the effects of dietary intervention on systemic and tumor immunity - Assess the effect of dietary intervention on overall gut microbiome composition and networks at 12 weeks and maintenance at 24 weeks - Assess the effects of dietary intervention on gut metabolic output and systemic metabolism at 12 weeks and maintenance at 24 weeks - Assess the effects of dietary interventions on quality of life and other patient reported outcomes (PROs) at 12 weeks and maintenance at 24 weeks